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Abstract 
 
Background and purpose: In vivo detection of b-amyloid (Ab) plaques in Alzheimer’s disease 
(AD) is now possible with 11C-PiB positron emission tomography (PET). Conventionally, a 
cortical:cerebellar PiB uptake ratio threshold of 1.4-1.5 has been used to categorise at-risk 
subjects as ‘amyloid-positive’ and ‘amyloid-negative’. It has been suggested that this 
threshold is too conservative and may miss early amyloid pathology. We investigated the 
relationship between conventional and lower baseline 11C-PiB PET thresholds for raised 
amyloid load and the subsequent clinical and radiological progression of mild cognitive 
impairment (MCI) cases longitudinally.  
Methods: We serially determined the cortical amyloid load with 11C-PiB PET of 44 MCI 
subjects over two years and compared findings with those for 12 healthy controls (HC) and 5 
AD cases. 
Results: Twenty-four subjects were classified as normal Ab load at baseline with mean 
cortical PiB standard uptake value ratios (SUVR) between 1.2-1.5. Their cognitive status 
remained stable over time. Three of these cases increased their amyloid load above a 
threshold of 1.5 over two years. Twenty-seven ‘raised Ab’ MCI cases with baseline cortical 
SUVRs above 1.5, showed deteriorating cognition. 50% of these cases converted clinically to 
AD during the follow-up period.  
Conclusion: Use of a PiB SUVR threshold of >1.5 to categorise subjects as having raised 
amyloid missed 14.3%  of MCI cases who likely had Thal stage 1 or 2 pathology and showed 
a progressive Ab load increase over two years. Lowering the threshold for abnormally raised 
Ab to 1.3 abolished all false negatives but resulted in 75% of HCs being falsely diagnosed as 
raised amyloid subjects.  
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Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia and is characterised 
clinically by progressive impairment of cognitive function and altered behaviour in fully 
conscious subjects.1 AD is characterised histopathologically by the presence of cerebral 
extracellular fibrillary b-amyloid protein (Ab) deposits (plaques) and tau neurofibrillary 
tangles (NFT).2,3 Identifying subjects with Ab deposition as early as possible is important to 
better understand the time course of AD pathologies and for the development of early 
therapeutic interventions.2 
Positron emission tomography (PET) imaging of Ab fibrils has now become possible in vivo 
using markers such as carbon-11 labelled Pittsburgh compound-B (11C-PiB),  a neutral 
thioflavin T analogue which crosses the blood-brain barrier and binds to Ab plaques in post-
mortem AD brain slices.4 Correct classification of individuals as raised and normal Ab load 
with amyloid PET is clinically important as it can help support or reject a clinical diagnosis of 
AD. PET can also detect aggregated Ab pathology in cases at higher risk of dementia such as 
subjects with mild cognitive impairment (MCI) or who carry susceptibility genes. However, 
different PET signal thresholds for defining amyloid-positivity have been used across centres 
depending on the camera used and analytical approach for modelling tracer uptake.5–11  
The pathological distribution of senile amyloid plaques has been described and rated 
according to Thal staging based on histochemical methods in 5 phases, symptomatic AD 
cases usually have a phase 3-5 extent of amyloid deposition.12  
Conventionally, cortical:cerebellar PiB standard uptake ratios (SUVRs) above 1.4-1.5 
measured 40-60 or 60-90 minutes after intravenous tracer administration have been taken as a 
threshold for defining raised Ab load in subjects. However, it has been suggested by 
Villeneuve and co-workers13 that using such a high PiB SUVR threshold may categorise early 
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Thal phase 1 and 2 amyloid cases as normal and that lower, more conservative thresholds are 
needed in order to detect early AD pathology. Thal and colleagues concluded that 
conventional amyloid PET analyses detect only phase 3 – phase 5 stages of Ab pathology as 
having raised amyloid load in preclinical, prodromal, and established AD cases.14  
The aim of our longitudinal PET study was to investigate how a cohort of MCI cases 
categorised as either high amyloid load or normal using both conventional and lowered 
baseline PiB SUVR thresholds subsequently progressed both clinically and with regard to 
changes in amyloid load over the following two years. In view of the possibility of missing 
early Thal phase 1 and 2 cases, the longitudinal findings for MCI subjects with baseline 
cortical PiB SUVR values lying between 1.2-1.5 were particularly monitored.  
 
Methods 
Study subjects 
Forty four MCI subjects and 12 healthy controls (HC) were enrolled into our longitudinal 
study, recruited from Dementia/Memory clinics in Denmark and by advertisement. MCI 
subjects with a history of worsening memory complaints corroborated by an informant were 
recruited for the study, as reported previously.5 Subject age ranged between 50-85 years. 
Enrolled subjects had a modified Hachinski Ischemic Scale score ≤4, and a Geriatric 
Depression Scale (version with 15 questions) score ≤6. None had a neurological or psychiatric 
disorder, were taking drugs associated with cognitive impairment or had any contraindication 
for magnetic resonance imaging (MRI). The HCs had no complaints of memory decline. 
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Five AD subjects were recruited from Dementia clinics and were diagnosed according to the 
ICD-10 Alzheimer’s disease criteria15 ; they fulfilled the same inclusion and exclusion criteria 
as MCI subjects.  
All subjects underwent 11C-PiB PET and were assessed with a standard neuropsychological 
test battery along with general cognition (Mini-Mental State Examination (MMSE), Montreal 
Cognitive Assessment (MoCA) and Clinical Dementia Rating (CDR) scores).  
The study was approved by the Central Denmark Region Committees on Health Research 
Ethics in accordance to the Declaration of Helsinki. All subjects provided written informed 
consent prior to participating. 
 
 
Image processing 
MRI and PET were acquired as previously described.5 High-resolution 3D T1-weighted 
magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Skyra Magnetom, 
Siemens, Erlangen, Germany) and used for structural coregistration of PET and to define 
cerebral grey matter masks. 11C-PiB PET scans were acquired with a High Resolution 
Research Tomograph (ECAT HRRT; CTI/Siemens, Knoxville, TN) using a previously 
published scan protocol.5 A target dose of 400 MBq 11C-PiB was intravenously injected over 
10 seconds, followed by a 10 ml saline flush. PET emission data were acquired for 50 
minutes in list mode 40-90 minutes post injection. 
MINC software (http://en.wikibooks.org/wiki/MINC)16 was used to segment MRI volumes 
into images of cerebral grey (GM) and white (WM) matter and cerebrospinal fluid (CSF).17 
GM masks were convolved with a probabilistic atlas18 to define regions of interest (ROIs) on 
each individual’s GM template. The spatially normalized PiB images were summed from 60-
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90 minutes and voxel signals were divided by the mean signal from the cerebellar GM to 
generate PiB SUVR images.19 To minimize spill-in/spill-out contamination, images were not 
smoothed prior to sampling activity from the composite cortical volume of interest. The 
composite cortical PiB SUVR was computed as a volume-weighted average of frontal, lateral, 
posterior temporal, precuneus, parietal and posterior cingulate cortical ROIs. 
 
Statistical analysis: 
Data were statistically interrogated using STATA version 14.2 (StataCorp LP, Texas, USA). 
Group differences in non-imaging variables were assessed using t-tests, Pearson’s c2 tests for 
categorical variables, and Wilcoxon rank-sum tests for skewed ordinal variables. P-values < 
0.05 were considered statistically significant.  
 
Determining amyloid status: 
The initial threshold used in this report to assign MCI cases to raised and normal amyloid 
load categories was a composite cortical:cerebellar PiB SUVR of 1.5 as the baseline ratio 
distribution was bimodal with a clear separation between raised MCI and control ranges at 
this ratio.5 Following this initial analysis, the effects of lowering the SUVR threshold to 1.3 to 
categorise groups as raised and normal amyloid was examined. Assignment of individuals to 
a raised or normal amyloid load group was then compared with their clinical and PiB PET 
outcomes after longitudinal follow-up for two years.  
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Results  
Demographics and cognitive ratings are presented in Table 1. Forty-four MCIs and 12 HCs 
had baseline PiB PET and 24 of these subjects (16 MCIs and 8 HC; mean baseline age 66 
years; range 50-79 years), had baseline composite cortical PiB SUVRs ranging between 1.2-
1.5. Of these, 15 MCIs and 6 HCs completed their 2-year follow-up. Twenty-seven MCI 
cases had a raised baseline composite cortical SUVR above 1.5 and 23 of these returned for 
their 2-year follow-up PiB PET and neuropsychological assessment (figure 1).  
When we surveyed the low PiB-uptake cases with baseline composite cortical SUVRs below 
1.5, one subject was excluded from the analysis. Although initially diagnosed as MCI, this 
subject developed clinical progressive supranuclear palsy (PSP) during follow-up, which is 
usually due to a tauopathy rather than Alzheimer’s pathology.  
Over two years 39 MCIs in total returned for their 2-year follow-up (24.5 ± 1.8 months). An 
overall 0.15 ± 0.26 increase in mean PiB SUVR was seen across all 39 MCIs over two years 
(P=0.0008), detailed regional cortical SUVR values are presented in table 2. A non-significant 
mean increase (0.072 ± 0.14, P=0.15) was observed over two years for the HC group, in line 
with previous findings.20 Individual changes and grouping of all subjects are presented in 
figure 1.   
 
Normal PiB group (SUVRs 1.2-1.5):  
Individual changes in composite cortical PiB SUVR for the normal PiB cohort (MCIs and 
HCs) are shown in figure 2A. Interrogating the combined composite cortical PiB SUVRs for 
these 21 normal PiB SUVR subjects with a paired t-test showed no significant mean change 
over two years (P=0.08).  
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However, three subjects (3 MCIs) individually changed their PET status over two years from 
a normal composite cortical PiB SUVR below 1.5 to one raised above 1.5 (Fig. 2A). At 
baseline, these three subjects all fell in the SUVR range of 1.3-1.5 and, of these three, one 
MCI showed an increase in SUVR of more than 20% over two years. This subject also 
showed deteriorating cognitive rating over two years (MMSE 26 to 24, MoCA 20 to 19, 
CDR-SOB 3 to 4.5) and was an APOE4 carrier. The other two MCI cases also showed SUVR 
increases greater than the reported 7% test-retest variability (9 and 11 %),21,22 although their 
cognitive scores stayed stable.  
 
1.4-1.5 SUVR subgroup (figure 2B): 
 
Four subjects had baseline PiB SUVRs lying between 1.4-1.5 (2 MCIs and 2 HC) - the two 
MCIs have been described above. Changes in the two HC SUVRs over two years were within 
the range of test-retest variability. 
 
1.3-1.4 SUVR subgroup (figure 2C): 
 
Nine subjects (8 MCIs and 1 HC), Fig. 2C, fell in a PiB SUVR range of 1.3-1.4. The majority 
of their SUVRs stayed stable and changes seen were in the range of test-retest variability. 
Three MCIs had SUVRs that increased by 8 % or more but only 1 MCI, reached a threshold 
of 1.5 - all were cognitively stable.  
 
Below 1.3 SUVR subgroup (figure 2D): 
 
Eight subjects fell in this subgroup and two - both HCs - showed an 8-9% increase in SUVR 
over two years (Fig. 2D). All the PiB-SUVRs remained below 1.4, and the cognitive status of 
the group remained stable.  
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The mean cognitive ratings (MMSE, CDR-SOB, MoCA) remained stable for the normal 
cohort (MCIs and HCs) with PiB SUVRs 1.2-1.5 over the 25.8 ± 3.1 months follow-up 
assessments (P=0.07 for MoCA) (Figure 3). The three subjects whose PiB SUVRs rose above 
a 1.5 threshold over two years are marked with unfilled triangles in figures 2 and 3. Two of 
these three had stable cognitive  ratings. The third subject showed a significantly lower 
cognitive score along with their significant increase in amyloid load. A fourth subject in the 
1.2-1.5 PiB SUVR group also showed a significant cognitive decline but their amyloid load 
remained stable. Their worsening cognition, therefore, may reflect the presence of a 
pathology other than AD.  
 
High PiB Group (PiB SUVR >1.5): 
Twenty-seven of our 44 MCIs had a baseline composite cortical SUVRs raised above 1.5 and 
23 (85%) of these returned for follow-up PiB PET and neuropsychological assessment after 
24.3 ± 1.2 months (Table 1). Four of our 12 HCs with normal cognitive scores had PiB SUVR 
values raised above 1.5 at baseline and these increased over time suggestive of the presence of 
preclinical AD. This finding is in line with previous reports.20,23–25  
MCI cases with raised SUVRs above 1.5 deteriorated significantly in their mean cognitive 
ratings (MMSE, MoCA and CDR SOB) over two years and the mean PiB SUVR value for 
this group increased significantly (mean 0.211 ± 0.323 SUVR (8.4 %); P=0.0048) - Table 1. 
The ApoE status was available for all but two of our subjects. Seventeen (63%) raised PiB 
subjects were carriers of the ApoE4 allele compared with only 4 (25 %) of the normal PiB 
group.   
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Figure 1 shows raised PiB group SUVR values over time in comparison with the normal PiB 
SUVR HC and AD cases. There was a clear SUVR separation of the raised and normal PiB 
MCI subgroups when using an SUVR threshold of 1.5 for abnormality at baseline. In our AD 
comparator group, none of the subjects had an SUVR below 2.0. 
 
Converters: 
Over two years, 13 (56%) of the 23 MCI subjects who returned for follow-up from the raised 
PiB group converted to clinical AD diagnosed according to ICD-10 criteria.15 The changes in 
PiB SUVRs for the converters are seen in Fig. 1. All but one of the AD converters, had a 
baseline PiB SUVR above 2.0 and nine (69%) were ApoE4 carriers.  
 
There was a difference in the prevalence of raised and normal PiB SUVR subjects recruited 
from dementia clinics and advertisements. Seventy-four percent of the raised PiB group 
subjects were recruited from Dementia clinics and only 26 % by advertisement whereas only 
35 % of the normal PiB group were recruited from Dementia clinics and 65 % came via 
advertisement. Sixty-nine percent of MCIs that converted to AD were recruited from a 
Dementia clinic.26  
 
Discussion 
A composite cortical SUVR value of 1.5 completely separated the normal range of MCI PiB 
SUVRs from the range of Alzheimer PiB SUVRs. The MCI subjects fell into two clear 
groups with raised and normal PiB SUVR using a 1.5 threshold for abnormality. However, 
because of the risk that some of the MCI cases with normal PiB SUVRs 1.2-1.5 may have had 
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occult Thal stage 1 or 2 amyloid we investigated the effect of lowering the threshold for 
abnormally raised amyloid from 1.5 to 1.3 and followed these subjects for two years. We 
reasoned that MCI cases with possible early amyloid deposition corresponding to Thal stages 
1 and 2 in our normal PiB uptake subjects would show increasing PiB SUVRs, possibly rising 
above our threshold of 1.5, over a two-year time period.  
We examined the changes in amyloid load and cognitive ratings over two years for 15 MCI 
subjects who had cortical PiB SUVRs between 1.2 and 1.5 and found that 10 of the 15 MCIs 
in this group showed no significant change in their amyloid load (≤8 % increase)21 or 
cognitive status. This suggests that early prodromal AD in these ten cases was not being 
missed using a 1.5 SUVR threshold. However, three normal PiB uptake MCIs, who fell in the 
SUVR range of 1.3-1.5, had PiB SUVRs that increased to above 1.5 over two years. Here we 
may have missed early AD pathology by using an SUVR threshold of 1.5 – one of these three 
MCIs had a baseline composite PiB SUVR on the borderline of 1.5. All the HCs with normal 
PiB SUVRs remained stable. Overall, the use of a PiB SUVR threshold of 1.5 led to 85.7 % - 
(18 of 21)  of the low PiB subjects being assigned a ‘correct’ amyloid normal diagnosis based 
on a two-year follow-up findings.13 All the 27 MCI cases who were categorised as amyloid 
positive with PiB SUVRs above 1.5 continued to show raised amyloid status and retained 
their diagnosis of prodromal Alzheimer’s disease.  
 
Three other cases with normal amyloid levels (2 MCIs and 1 HC) increased their cortical 
SUVRs over two years to a greater extent than could be explained by test-retest variability 
(>8 %),21,22 though none reached a PiB SUVR threshold of 1.5 (fig. 2A). It is possible that 
with a longer follow-up these cases would have reached our 1.5 threshold and have been 
recategorized as raised PiB SUVR and that they represent baseline Thal 1 or 2 phases.13 
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Against this conclusion, however, was the finding that their cognitive status did not 
deteriorate.  
Raising the threshold to above 1.5 – say 1.6-1.8 – does not improve specificity by reducing 
false positives, but sensitivity decreases as the risk of missing raised amyloid cases increases, 
in addition to categorising one clinical AD subject as normal (figure 1).  
Dropping the PiB threshold from 1.5 to 1.4 eliminated two of the three potential false 
negatives, but led to a further two HCs being scored as having raised amyloid. This would 
lead to a total of 6 out of our 12 HCs (50 %) becoming categorized as having raised PiB, a 
higher prevalence than reported by other series.20,23–25  
Dropping the PiB SUVR threshold further to 1.3 eliminated all the potential false negatives in 
our low PiB SUVR group, but 9 out of the 12 of the HCs (75%) now became scored as having 
raised amyloid. Seven (58 %) of the normal PiB SUVR MCIs also became incorrectly 
assigned as having raised amyloid based on follow-up clinical outcome. What is clear, 
however, is that baseline assignment of MCI cases to raised or normal amyloid categories 
becomes questionable if their PiB SUVR values lie close to a threshold value of 1.5 and both 
imaging and clinical follow-up is required in these borderline cases.6,27 This conclusion of 
course applies to findings using an HRRT PET camera. The optimal threshold for dividing 
raised and normal PiB SUVRs is likely to be lower - say 1.4 – for centres using a lower 
resolution PET-CT.  
In this study we focussed on older MCI subjects. A PiB SUVR threshold of 1.5 to delineate 
raised amyloid deposition may be too high when dealing with younger subjects. We also used 
a time window of 60-90 minutes rather than 40-60 minutes as used in some centres. A 60-90 
minute window will lead to a higher threshold for separating raised and normal  PiB SUVRs 
as the SUVR curves for PiB are still rising at 40 minutes.28 Additionally, PiB uptake by AD 
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cases is more prolonged than in HCs and plateaus later for subjects with significant PiB 
uptake.28 The choice of time window thus is dependent on several parameters including the 
scanner type, the injected dose and the population of interest. 
The raised PiB MCI group showed a significant deterioration in their mean cognitive scores 
over two years. Conversion to AD over time did not correlate with levels of amyloid load as 
reflected by cortical SUVRs.29 The majority (two thirds) of subjects in the raised PiB group 
were carriers of the ApoE4 allele as were 70% of the converters to AD, whereas only 25% of 
the normal PiB MCI subjects were ApoE4 carriers. One of our subjects clinically converted to 
AD with a PiB SUVR of 1.6 at baseline, which is low compared with all our other converters 
and showed no SUVR change at follow-up. This case was a carrier of the ApoE4 gene. 
Conversion of MCI to AD is based on clinical criteria, such as loss of  independence and 
progressing cognitive deficits.1,30 Conversion is, therefore, an individual judgement and this 
could have led to a questionable AD classification here. Alternatively, the subject may have 
had other pathology such as a tauopathy.  
The raised PiB SUVR group showed a mean increase in PiB SUVR over time. Some of these 
individuals showed decreases in PiB SUVR but these were all within the range of test-retest 
variability (<7 %) with one exception where a decrease of 12 % was seen. The cerebellar 
reference region activity for this subject remained stable over time.  
 
A limitation of our study is the absence of partial volume corrections for atrophy effects on 
PIB-SUVRs. Atrophy may have acted to lower PiB SUVRs by a few percent. No correlation 
was seen between the changes in PiB SUVR and changes in composite cortical ROI volume. 
Our use of a high resolution scanner will also have helped to minimise effects of atrophy over 
time.31 
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Our longitudinal PiB PET study on MCI cases suggests that, while the use of a current 
cortical SUVR threshold of 1.5 to define raised amyloid may lead to occasional false 
negatives, over 80% of cases are correctly assigned to raised or normal amyloid categories. A 
lowering of the threshold eliminated false negatives but resulted in a high percentage of false 
positive cases and reduced the specificity of identifying true negatives. Where cases have PiB 
SUVRs close to the cut off level of 1.4-1.5 then follow-up is required to make a confident 
assignment to an amyloid positive or negative status. Overall setting an SUVR threshold is a 
trade-off between eliminating false negatives generated and generating false positives by 
lowering the threshold in our series.  
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Table 1: Participant characterisation 
 MCI – normal PiB P value MCI – raised PiB P value Healthy control P value MCI (total) P value AD 
 Baseline 
(n=17) 
Follow up 
(n=16) 
 Baseline 
(n=27) 
Follow up 
(n=23) 
 Baseline 
(n=12) 
Follow up 
(n=10) 
 Baseline 
(n=44) 
Follow up 
(n=39) 
 Baseline 
(n=5) 
Age, years  66.2 ± 8.3 68.3 ± 8.5  73.3 ± 6.1 75.1 ± 5.9  68.8 ± 5.2 72.5 ± 4.4  70.6 ± 7.8 72.3 ± 7.8  96.8 ± 9.9 
Males/females 9/8 9/7  9/18 7/16  7/12 5/10  26/18 23/16  3/2 
Education, years 11.9 ± 3.5   12.5 ± 3.0   13.3 ± 2.5   12.3 ± 3.2   11.1 ± 2.7 
MMSE 27.8 ± 1.8 26.5 ± 2.5 0.084 26.8 ± 1.8 24.3 ± 3.8 0.0008* 28.8 ± 1.2 28.2 ± 1.3 0.21 27.2 ± 1.8 25.2 ± 3.4 0.0002* 23.0 ± 5.4 
CDR sum-of-boxes 1.0 [0.5; 2.5] 1.25 [0.0; 7.0] 0.099 3.5 [0.0;4.0] 5.5 [0.0;10.0] <0.0001* 0.0 [0.0; 
0.0] 
0.0 [0.0; 
1.0] 
0.5 1.5 [0.0; 4.0] 1.5 [0.0; 
10.0] 
<0.0001* 3.5 [2.5; 9.0] 
MoCA 25.7 ± 2.8a  24.8 ± 3.7 0.040* 23.6 ± 3.8 21.4 ± 4.8 0.01* 26.5 ± 1.6a 25.3 ± 2.8 0.33 24.4 ± 3.2a 22.8 ± 4.7 0.0024* 18.2 ± 5.7 
PiB dose, MBq 410 ± 24.5 418 ± 14.5 0.35 367 ± 78 390 ± 56 0.40 422 ± 27.5 401 ± 30.3 0.09 384 ± 66  401 ± 46 0.3 416 ± 18 
PiB SUVR 1.325 ± 0.07 1.4 ± 0.15 0.013* 2.53 ± 0.53 2.71 ± 0.51 0.0048* 1.49 ± 0.32 1.60 ± 0.44 0.15 2.06 ± 0.73 2.17 ± 0.76 0.0008* 3.14 ± 0.88 
Apoe E4, n (%) 4 (24 %)b 4 (25 %)b  17 (62 %)b 16 (69 %)b  3 (27 %)b 2 (22 %)b  21 (50 %)c 20 (51 %)  1 (30 %)a 
Follow up (month)  24.8 ± 2.5   24.3 ± 1.2   26.1 ± 3.8    24.5 ± 1.8   
Table 1: Participant characterisation. Normal and raised PiB defined as below and above 1.5 SUVR, respectively. Normally distributed data 
are presented in mean ± SD. Not normally distributed data are presented in median and [range]. n = number; MMSE = minimental state 
examination; CDR = clinical dementia rating; MoCA = Montreal Cognitive Assessment. P-values of paired tests between baseline and 
follow up. * significant P values, a2 missing values, b1 missing value, c 6 missing values. 
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Table 2: Regional SUVR values 
 Normal PiB group High PiB group 
 Baseline Follow-up Baseline Follow-up 
N 21 21 23 23 
Frontal cortex 1.35 ± 0.069 1.42 ± 0.17 2.53 ± 0.58 2.74 ± 0.52* 
Temporal cortex 1.17 ± 0.087 1.20 ± 0.10 1.96 ±0.39 2.13 ± 0.42* 
Parietal cortex 1.41 ± 0.096 1.46 ± 0.16 2.51 ± 0.50 2.72 ± 0.48* 
Anterior cingulate 1.41 ± 0.21 1.50 ± 0.11 2.70 ± 0.63 2.94 ± 0.60* 
Posterior cingulate 1.46 ± 0.12 1.47 ± 0.19 2.78 ± 0.63 3.03 ± 0.60* 
Precuneus  1.35± 0.089 1.42 ± 0.16 2.89 ± 0.69 3.14 ± 0.67* 
Composite  1.33 ± 0.081 1.37 ± 0.14 2.50 ± 0.54 2.71 ± 0.51* 
Table 2: Regional and composite PiB SUVR values in normal and high PiB group. N= 
number. The baseline to follow up time is 2 years. Data presented in mean±SD. *Statistically 
significant difference from baseline by two-sample t-test (p<0.05). 
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Figure 1: 
 
Figure 1: Scatterplots showing individual baseline and follow-up PiB SUVR values in the HC, MCI, and AD groups. The time-range 
between baseline and follow is 2 years. Blue lines and dots indicate normal-PiB cases. Red lines and dots indicate raised PiB cases. Purple 
dashed line in the MCI group indicates one progressive supranuclear palsy subject. Black lines in the MCI group indicate the converters to 
AD. 
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Figure 2: 
 
 
Figure 2: Changes in MCI and HC subjects in the normal PiB-group. The time-range between 
baseline and follow is 2 years. Full lines represent MCI subjects and dashed lines represent 
HC. A: The 3 subjects crossing the 1.5 threshold are marked with unfilled triangles. B: 
Changes in 4 subjects with baseline PiB SUVR values between 1.4-1.5. C: Changes in 8 
subjects with PiB SUVR values between 1.3-1.4. D: Changes in 9 subjects with PiB SUVR 
values below 1.3.  
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Figure 3: 
 
Figure 3: Cognitive scores of MCI and HC subjects in the raised PiB- (circles) and normal PiB-group (triangles). Unfilled circles indicate 
the AD-converters amongst the raised PiB-group. Unfilled triangles indicate the three subjects who crosses the 1.5 threshold. Time-range 
between baseline and follow-up is 2 years. MoCA = Montreal Cognitive Assessment; CDR-SOB = clinical dementia rating – sum of boxes; 
MMSE = minimental state examination.  
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